RALEIGH, N.C. , June 21, 2017 /PRNewswire/
-- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark
extending access to both BELBUCA ® (buprenorphine) buccal film (CIII) and BUNAVAIL
® (buprenorphine and naloxone) buccal film (CIII) through 2020. The agreement is important as
CVS/Caremark represents a significant portion of the covered lives in the United States.
BDSI reacquired BELBUCA from Endo Pharmaceuticals in January 2017 and subsequently
relaunched the product. Prescription sales for BELBUCA reached their highest point in May
2017 since the product was launched by Endo in early 2016 and continues to grow in June. Weekly sales for BELBUCA
for the week ending June 9, 2017 (1,657 prescriptions) exceeded the previous peak from December 2016 for the first time according to data from Symphony Health.
"We are pleased with the momentum we are beginning to see with BELBUCA as well as the execution of new managed care
contracts, such as the CVS/Caremark agreement which goes through 2020," said Dr. Mark A. Sirgo,
President and Chief Executive Officer of BDSI. "We have seen an overall increase in BELBUCA sales since relaunching the
product, and for the first time, we recently exceeded both monthly and weekly sales levels achieved by Endo, suggesting that our
current strategy, although early in the process, appears to be working as planned. Furthermore, we believe the continued
focus on responsible use of opioids and actions taken by FDA in this regard bode well for BELBUCA's growth
prospects."
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas
of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive
(BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in
partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical
needs.
BDSI's development strategy focuses on the utilization of the FDA's 505(b)(2) approval process. This regulatory pathway
creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSI's area of focus is the development and commercialization of products in the areas of pain management and addiction.
These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet
medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as
breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. BDSI's headquarters is
in Raleigh , North Carolina.
For more information, please visit or follow us:
Internet:
www.bdsi.com
Facebook: Facebook.com/BioDeliverySI
Twitter:
@BioDeliverySI
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal
film (CIII) are marketed in the U.S. by BioDelivery Sciences. ONSOLIS ® (fentanyl buccal
soluble film) (CII) is licensed in the U.S. to Collegium Pharmaceutical pursuant to the U.S. licensing and development agreement
between BDSI and Collegium. For full prescribing information and important safety information on BDSI products, including
BOXED WARNINGS for ONSOLIS, please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or
contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety
information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release any statements of employees, representatives and partners of BioDelivery Sciences International, Inc.
(the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks
and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and
Exchange Commission. Actual results (including, without limitation, the actual impact on the Company's sales as a result of
the managed care contract described herein) may differ significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by
applicable law.
BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered
trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks
owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective
owners.
© 2017 BioDelivery Sciences International, Inc. All rights reserved.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biodelivery-sciences-announces-agreement-with-cvscaremark-for-belbuca-and-bunavail-through-2020-300477471.html
SOURCE BioDelivery Sciences International, Inc.